SELLAS Life Sciences Group, Inc.
NASDAQ:SLSBiotechnology
+$0.31 today
- Market cap
- $3.90B
- Beta
- 2.53
- P/E (TTM)
- -47.3
- EPS (TTM)
- -$0.17
Volume 119.49M
Average 7.79M
SLS Operating Margin
Operating income as a percentage of revenue, showing the profitability of core operations.
SELLAS Life Sciences Group, Inc.NASDAQ: SLS
Operating Margin · Q3 FY2026 · quarter ended Sep 2026
Operating margin not reported for Q3 FY2026
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Margin history
Percent of revenue · from the income statement
- Latest · FY2022
- -4195.0%
- Year-over-year change
- -3862.2pp
| Period | Period end | Operating Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | — | — |
| FY2024 | 2024-12-31 | — | — |
| FY2023 | 2023-12-31 | — | — |
| FY2022 | 2022-12-31 | -4195.0% | -3862.2pp |
| FY2021 | 2021-12-31 | -332.8% | — |
Operating Margin vs competitors
How SLS compares with its peers on the latest reported figures
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Aug 2026 | 41.3% | +360.6 pp | +135.8 pp | |
| LTM Jun 2026 | 31.6% | +10.4 pp | +8.7 pp | |
| LTM Mar 2026 | -40.5% | +24.7 pp | +32.2 pp | |
| LTM Mar 2026 | -81.4% | +5066.4 pp | +49.9 pp | |
AAPGAscentage Pharma Group International | FY2025 | -211.1% | -173.4 pp | +194.1 pp |
| LTM Mar 2026 | -326.6% | -33.6 pp | +125.9 pp | |
| LTM Mar 2026 | -503.2% | +1496.5 pp | — | |
| LTM Mar 2026 | -1372.9% | — | +61796.9 pp | |
| FY2025 | -3084.8% | +297.6 pp | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding SLS) | -211.1% | +161.2 pp | +125.9 pp | |
Competitors are the stored peer set for SLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 7.6M | 1M | 0 | 0 | 0 |
| Cost of Revenue | 200K | 100K | 0 | 0 | 0 |
| Gross Profit | 7.4M | 900K | 0 | 0 | 0 |
| Gross Margin | 97.4% | 90.0% | — | — | — |
| Research & Development | 21.37M | 30.27M | 24.01M | 19.1M | 16.02M |
| Selling, General & Admin | 11.32M | 12.58M | 13.86M | 12.42M | 12.25M |
| Operating Expenses | 32.69M | 42.85M | 37.87M | 31.51M | 28.27M |
| Depreciation & Amortization | 1.27M | 457K | 37.87M | 31.51M | 0 |
| EBITDA | (18.32M) | (31.49M) | 529K | 632K | (26.86M) |
| EBITDA Margin | -241.1% | -3149.3% | — | — | — |
| Operating Income | (25.29M) | (41.95M) | (37.87M) | (31.51M) | (28.27M) |
| Operating Margin | -332.8% | -4195.0% | — | — | — |
| Interest Income | 6K | 317K | 525K | 632K | 1.41M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4.36M | 649K | 529K | 632K | 1.41M |
| Income Before Tax | (20.94M) | (41.3M) | (37.34M) | (30.88M) | (26.86M) |
| Pre-Tax Margin | -275.5% | -4130.1% | — | — | — |
| Income Tax Expense | (237K) | 0 | 0 | 0 | 0 |
| Net Income | (20.7M) | (41.3M) | (37.34M) | (30.88M) | (26.86M) |
| Net Margin | -272.4% | -4130.1% | — | — | — |
| EPS (Basic) | (1.34) | (2.13) | (1.34) | (0.50) | (0.25) |
| EPS (Diluted) | (1.34) | (2.13) | (1.34) | (0.50) | (0.25) |
| Weighted Avg Shares | 15.48M | 19.4M | 27.78M | 61.2M | 109.05M |
| Weighted Avg Shares (Diluted) | 15.48M | 19.4M | 27.78M | 61.2M | 109.05M |
SELLAS Life Sciences Group, Inc.
NASDAQ:SLS
Intrinsic Alpha fair value
Locked
Current Price
$19.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.